

FcResolv™ NOG Portfolio

The First and Only Super Immunodeficient Mouse Models that Remove Murine Fc Gamma Receptors Known to Confound Results

Murine Fc gamma receptors (FcγRs) can confound preclinical studies involving antibody-based therapies, causing false positives or false negatives that lead to incorrect conclusions and derail drug discovery. By knocking out these receptors, FcResolv™ NOG models provide clarity in antibody-based drug studies, offering greater confidence and more translatable data while utilizing fewer resources.

FcResolv models are suitable for engrafting a wide range of human cells and tissues, including simultaneous human tumor engraftment and immune system humanization.

KEY THERAPEUTIC AREAS

- ▶ Oncology and immuno-oncology
- ▶ Autoimmune disease
- ▶ Any therapeutic approach involving antibody-based drugs containing an Fc domain



KEY BENEFITS

GREATER CONFIDENCE IN YOUR STUDY RESULTS

- ▶ Eliminate false negatives that result when an antibody-based therapeutic's Fc domain interacts with murine FcγRs
- ▶ Eliminate false positives that result when FcγRs trigger residual murine immune activity

MORE ACCURATE ASSESSMENT OF ANTIBODY-BASED THERAPIES

- ▶ Distinguish true drug efficacy from off-target effects mediated through the mouse immune system, without deconvolution steps
- ▶ Gain clarity on therapeutic mechanism of action without interference from murine FcγR activity









BETTER ANSWERS WITH FEWER RESOURCES

- ▶ Avoid wasteful investments based on false positives or missing out on promising candidates due to false negatives
- ▶ Gain more reliable answers faster using fewer studies and animals

HOW FcResolv NOG MODELS WORK

The FcResolv NOG model portfolio is based on the super immunodeficient CIEA NOG mouse[®]. This highly versatile strain lacks adaptive immune cells and has an attenuated innate immune response, yet still retains some residual mouse immune cells that can interact with therapeutic antibodies. FcResolv NOG models eliminate this interaction by knocking out the activity of all murine FcγRs, including the FcγRI, IIB, III and IV types, along with the high affinity FcεRI receptor. The low affinity FcεRII receptor remains present.

Alleviate False Positives Generated by Murine Innate Cell-Mediated ADCC or ADCP

<p>CIEA NOG mouse[®]</p>  <p>Murine FcγR activity intact</p>			<p>Wrong Answer</p>  <p>False positive tumor regression acting through antibody-dependent mechanism mediated by murine FcγRs on mouse innate immune cells</p>
<p>FcResolv NOG mouse</p>  <p>Murine FcγR activity knocked out</p>			<p>Right Answer</p>  <p>No confusing false positives from FcγR interactions when using FcResolv NOG models</p>

FcγRs can confound experiments involving antibody-based therapies in several ways. This graphic depicts one mechanism for how knockout of Fc gamma receptors alleviates false positives.

GET TO THE RIGHT ANSWER FASTER FOR YOUR ANTIBODY-BASED THERAPY

Use the only super immunodeficient mouse model that lacks murine FcγRs to gain greater confidence in evaluating your antibody-based therapy.

Model Number	Name	Description
19164	FcResolv NOG	Ideal for tumor xenografts using cell lines or patient-derived tumors, engraftment of other normal or pathological human cells and tissues, and immune system humanization studies
19220	FcResolv hIL-15 NOG	Supports engraftment of human NK cells, for use in efficacy studies on antibody-based therapeutics with an antibody-dependent cellular cytotoxicity (ADCC) mechanism of action

Get in touch for more information or to schedule a consultation on FcResolv NOG models.

US: 1-888-822-6642 | EU: +45 70 23 04 05 | info@taconic.com

Learn more at: taconic.com/fcresolv